<DOC>
	<DOC>NCT00522795</DOC>
	<brief_summary>Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001</brief_summary>
	<brief_title>Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)</brief_title>
	<detailed_description>32 patients with esophageal or gastroesophageal junction cancer will receive Radiation:50.4 Gy at 180cGy fraction/day for 28 treatments and Paclitaxel Poliglumex (PPX) and Cisplatin weekly times 6 followed by surgery.</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients are required to have pathologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction Patients may have celiac adenopathy There must be no evidence of distant organ metastases No prior chemotherapy or radiation for esophageal cancer Patients must be &gt; 18 years of age, and non pregnant Patients must have an ANC &gt; 1,500/ul, platelets &gt; 100,000/ul, creatinine &lt; 2.0 and bilirubin &lt; 1.5 x ULNECOG performance status 01. Female patients, must either be not of child bearing potential or have a negative pregnancy test within 14 days of starting study treatment. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal. Pregnant or lactating females are not eligible No contraindications to esophagectomy Signed informed consent Active or uncontrolled infection Patients must not have other coexistent medical condition that would preclude protocol therapy. Any concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s).</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Esophageal Cancer</keyword>
</DOC>